The decline is the result of manufacturing limits related to an FDA injunction that was approved last week, according to a press release.
The cuts represents about 40% of the Ohio facility’s total workforce. The remaining 222 employees will either remain in their current roles or be reassigned to other roles on the Elyria site, the company noted.
"While we regret having to take this step, we recognize the need to align our workforce with our production volume," president & CEO Gerry Blouch said in prepared remarks. "We remain committed to achieving full regulatory compliance and to resuming full operations at Taylor Street as quickly as possible. Over the past year, we have made significant investments of time, people and resources to achieve regulatory compliance and make Invacare’s Taylor Street manufacturing facility an even stronger operation."
The FDA injunction requires that Invacare limits manufacturing at the Elyria campus as well as another site until the company regains full compliance with FDA regulations, according to Bloomberg.